Skip to main content

Evogene Ltd.

For the period ended Apr 2, 2026. Filed Apr 2, 2026.

View on SEC.gov

About this filing

What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.

Apr 2, 2026 · Filed Apr 2, 2026

Use the contents to explore the available documents and sections.

EVGN$0.27-17.8%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits

EX-99.1 · Forward-Looking Statements

Forward-Looking Statements

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as “may,” “could,” “expects,” “hopes,” “intends,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates,” “demonstrates” or words of similar meaning. For example, Evogene has utilized forward-looking statements in this press release when it discusses its ability to regain compliance with Nasdaq’s Listing Qualification requirements including by potentially effecting a reverse stock split to regain compliance with the $1.00 minimum bid price requirement. Actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene, including, the ongoing war between Israel and the United States against Iran and its sponsored terrorist group, Hezbollah, as well as those additional risk factors identified in Evogene’s reports filed with the applicable securities authority. In addition, Evogene relies, and expects to continue to rely, on third parties to conduct certain activities, such as field-trials and pre-clinical studies, and if those third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections or assumptions.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.